>90%
of AD dementia patients have neurpsychiatric symptoms
Our lead program is currently in a Phase 2/3 clinical study, targeting agitation associated with Alzheimer’s disease dementia.
of AD dementia patients have neurpsychiatric symptoms
Neurodegenerative diseases like AD are characterized by progressive neuronal cell death resulting in overall brain atrophy.
At the advanced stages of the disease, with more widespread and generalized brain atrophy, patients experience a wider spectrum of symptoms that often present as overlapping clusters.
This leads to symptoms including agitation/aggression, anxiety, depression, apathy, irritability, disinhibition, and delusions/hallucinations, which together form a complex cluster of neuropsychiatric symptoms (NPS) in dementia.
Calms brain overactivity by blocking NMDA receptors
Has been used safely in medicine for over 60 years.
Slows degradation of Dextromethorphan by inhibiting CYP2D6 in the liver
Blocks 5-HT2A/2C receptors which may have impact on several neuropsychiatric symptoms
No safety concerns identified in >2,500 subjects tested exposed to Deramciclane for up to 1 year
When combined, this pharmacological approach offers the opportunity to treat neuropsychiatric symptoms associated with dementia without affecting the dopaminergic system, avoiding an acceleration of cognitive decline, and increased risk for morbidity and mortality.
